We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 22, 2020

Increased VTE Risk in Patients With HR+,HER2− MBC Treated With CDK4/6 inhibitors + Endocrine Therapy vs Endocrine Therapy Alone

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Venous Thromboembolism Risk in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With Combined CDK 4/6 Inhibitors Plus Endocrine Therapy Versus Endocrine Therapy Alone: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Breast Cancer Res Treat 2020 Sep 01;183(2)479-487, KZ Thein, TW Htut, S Ball, S Swarup, A Sultan, TH Oo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading